English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/129304
COMPARTIR / IMPACTO:
Estadísticas
logo share SHARE   Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Título

Identification of p190RhoGEF in the Gα13 signaling pathway

AutorMasià-Balagué, Miriam ; Izquierdo, Ismael; Garrido, Georgina ; Aragay, Anna M.
Fecha de publicación3-sep-2013
CitaciónXXXVI Congreso de la Sociedad Española de Bioquímica y Biología Molecular (2013)
ResumenSignaling via GPCRs has been implicated in a myriad of physiological and pathological processes. The G¿12 and G¿13 proteins comprise one of the families of the heterotrimeric G proteins and are known for their regulation of actin cytoskeleton and epithelial cell junctions, as well as in the progression of tumor cells and cancer metastasis. The most extensively characterized downstream mediators of signaling through the G12 subfamily are the members of the Rho family GTPases. G¿12 and G¿13 interact and stimulate the activity of RGS-RhoGEFs sub-family, characterized by their binding to G proteins through their RGS domain. We identified G¿13 as a novel regulatory protein interacting with the non-RGS-RhoGEF p190RhoGEF, known to regulate FAK signaling downstream of GPCRs and involved in promoting tumor progression. We elucidated the involvement of p190RhoGEF in the G¿13 signaling pathway promoting Rho GTPase activation. Moreover, knock-down of G¿13 protein prevents both RhoA activation and paxillin tyrosine phosphorylation upon gastrin stimulation in colon cancer cells. Together, our findings dissect and suggest the existence of a new molecular mechanism of signal transduction through the gastrin-CCK2R and suggest a crucial role of G¿13 in the activation of p190RhoGEF and, probably, in the regulation of neuroendocrine and colon cancer motility and invasion. According to the obtained results, the possible benefit of targeting G¿13 to inhibit gastrin action as a therapy in several gastro-intestinal diseases to treat cancers expressing the CCK2R should be considered.
DescripciónPóster presentado en el XXXVI Congreso de la Sociedad Española de Bioquímica y Biología Molecular SEBBM, celebrada del 3 al 6 de septiembre de 2013 en Madrid (España)
URIhttp://hdl.handle.net/10261/129304
Aparece en las colecciones: (IBMB) Comunicaciones congresos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.